Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 83, Issue 1, 2009, Pages 117-118

  Ikeda, Hiroki ^a,b   Hamamoto, Yoshiyuki ^a,b   Honjo, Sachiko ^a   Nabe, Koichiro ^a   Wada, Yoshiharu ^a   Koshiyama, Hiroyuki ^a,b  

^a Kitano Hospital   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker (ARB); Diabetic nephropaty; Hypertension; Microalbuminuria; Olmesartan

Indexed keywords

CANDESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; JAPANESE; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN;

AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 57949096142     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.10.013     Document Type: Article

References (10)

1. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Collaborative Study Group: renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
2. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group: the effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
3. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. RENAAL Study Investigators: effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
4. Viberti G., and Wheeldon N.M. Microalbuminuria reduction with valsartan (MARVAL) study investigators: microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106 (2002) 672-678
5. Benson S.C., Pershadsingh H.A., Ho C.I., Amar Chittiboyina, Prashant Desai, Michal Pravenec, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension 43 (2004) 993-1002
6. Pugsley M.K. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc 48 (2005) 35-38
7. Miura S., Fujino M., and Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 1 2 (2005) 115-121
8. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 27 Suppl. 1 (2004) S79-S83
9. Miura S.I., Fujino M., Hanzawa H., Kiya Y., Imaizumi S., Matsuo Y., et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem. 281 July (28) (2006) 19288-19295
10. Mizuno M., Sada T., Kato M., and Kike H. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 25 (2002) 271-278